The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Novel Effect of Antihelminthic Niclosamide on S100A4-Mediated Metastatic Progression in Colon Cancer
Open accessAbstract
BACKGROUND: Metastasis formation in colon cancer severely reduces the survival rate in patients. S100A4, a calcium-binding protein, is implicated in promoting metastasis formation in colon cancer. METHODS: To identify a transcription inhibitor of S100A4, high-throughput screening of 1280 pharmacologically active compounds was performed using a human colon cancer cell line expressing a S100A4 promoter-driven luciferase (LUC) reporter gene construct (HCT116-S1004p-LUC). Niclosamide, an antihelminthic agent, was identified as a potential candidate. Colon cancer cell lines (HCT116, SW620, LS174T, SW480, and DLD-1) were treated with 1 μM niclosamide to analyze the effect on S100A4 mRNA and protein expression by quantitative reverse transcription-polymerase chain reaction and immunoblot assays, and effects on cell migration, invasion, proliferation, and colony formation were also assessed in vitro. The effect of niclosamide on liver metastasis was assessed in a xenograft mouse model of human colon cancer (n = 8 mice) by in vivo imaging. The long-term effect of niclosamide on metastasis formation after discontinued treatment was quantified by scoring, and overall survival (n = 12 mice) was analyzed by Kaplan-Meier method after discontinuation of treatment. All statistical tests were two-sided. RESULTS: Reduced S100A4 mRNA and protein expression, and inhibited cell migration, invasion, proliferation, and colony formation were observed in niclosamide-treated colon cancer cells in vitro. In vivo imaging of niclosamide-treated mice showed reduced liver metastasis compared with solvent-treated control mice (n = 4 mice per group). Compared with the control group, discontinuation of treatment for 26 days showed reduced liver metastasis formation in mice (n = 6 mice per group) (control vs discontinuous treatment, mean metastasis score = 100% vs 34.9%, mean difference = 65.1%; 95% confidence interval [CI] = 18.4% to 111.9%, P < .01) and increased overall survival (n = 6 mice per group; control vs discontinuous treatment, median survival = 24 vs 46.5 days, ratio = 0.52, 95% CI = 0.19 to 0.84, P = .001). CONCLUSION: Niclosamide inhibits S100A4-induced metastasis formation in a mouse model of colon cancer and has therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Screen for Chemical Modulators of Autophagy Reveals Novel Therapeutic Inhibitors of mTORC1 Signaling
Balgi, A. D., Fonseca, B. D., Donohue, E., Tsang, T. C. F., Lajoie, P., Proud, C. G., Nabi, I. R., & Roberge, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007124 · Cited by 344
Cited by
Donato, R., R. Cannon, B., Sorci, G., Riuzzi, F., Hsu, K., J. Weber, D., & L. Geczy, C. (2013) · Current Molecular Medicine · doi:10.2174/156652413804486214 · Cited by 1,316
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Damage-associated molecular patterns in cancer: a double-edged sword
Hernandez, C., Huebener, P., & Schwabe, R. F. (2016) · Oncogene · doi:10.1038/onc.2016.104 · Cited by 480
Niclosamide: Beyond an antihelminthic drug
Chen, W., Mook, R. A., Premont, R. T., & Wang, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2017.04.001 · Cited by 444
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
Li, Y., Li, P.-K., Roberts, M. J., Arend, R. C., Samant, R. S., & Buchsbaum, D. J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.003 · Cited by 364
Metadata
- Authors
- Sack, U., Walther, W., Scudiero, D., Selby, M., Kobelt, D., Lemm, M., Fichtner, I., Schlag, P. M., Shoemaker, R. H., & Stein, U.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-17
- Volume
- 103
- Issue
- 13
- Pages
- 1018-1036
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2098760354
- Cited by
- 212
- References
- 2
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Effect of Antihelminthic Niclosamide on S100A4-Mediated Metastatic Progression in Colon Cancer. https://app.cochat.ai/papers/10.1093/jnci/djr190
- The paper
- Sack, U., Walther, W., Scudiero, D., Selby, M., Kobelt, D., Lemm, M., Fichtner, I., Schlag, P. M., Shoemaker, R. H., & Stein, U. (2011). Novel Effect of Antihelminthic Niclosamide on S100A4-Mediated Metastatic Progression in Colon Cancer. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djr190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.